New York-based clinical stage biotechnology company Egret Therapeutics announced on Wednesday that it has named Dr Ron Cohen as its new director.

Previously, Cohen served as president, CEO and founder of Acorda Therapeutics and officer of Advanced Tissue Sciences, Inc. He has served on the boards of the Biotechnology Innovation Organization (BIO) and is past chair of the BIO Board, of BIO's Emerging Companies Section, and of the New York Biotechnology Association (NYBA).

Dr Cohen holds a BA degree in Psychology from Princeton University, and MD from the Columbia College of Physicians & Surgeons. He has completed a residency in Internal Medicine at the University of Virginia Medical Center and is also Board Certified in Internal Medicine.